Northern Trust’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-393,523
| Closed | -$13.2M | – | 4550 |
|
|
2026
Q1 | $13.2M | Buy |
393,523
+28,105
| +8% | +$1.1M | ﹤0.01% | 1924 |
|
|
2025
Q4 | $16.9M | Buy |
365,418
+11,184
| +3% | +$613K | ﹤0.01% | 1784 |
|
|
2025
Q3 | $23.9M | Buy |
354,234
+25,594
| +8% | +$1.9M | ﹤0.01% | 1563 |
|
|
2025
Q2 | $27.5M | Buy |
328,640
+96,304
| +41% | +$7.21M | ﹤0.01% | 1463 |
|
|
2025
Q1 | $16.6M | Buy |
232,336
+5,447
| +2% | +$265K | ﹤0.01% | 1745 |
|
|
2024
Q4 | $10.2M | Buy |
226,889
+34,309
| +18% | +$1.78M | ﹤0.01% | 2110 |
|
|
2024
Q3 | $9.72M | Buy |
192,580
+136,185
| +241% | +$6.52M | ﹤0.01% | 2081 |
|
|
2024
Q2 | $2.3M | Buy |
56,395
+22,427
| +66% | +$950K | ﹤0.01% | 2822 |
|
|
2024
Q1 | $1.45M | Buy |
33,968
+650
| +2% | +$29.4K | ﹤0.01% | 3135 |
|
|
2023
Q4 | $1.34M | Buy |
33,318
+26,288
| +374% | +$748K | ﹤0.01% | 3196 |
|
|
2023
Q3 | $207K | Buy |
+7,030
| New | +$42.6K | ﹤0.01% | 3803 |
|
|
2022
Q3 | – | Sell |
-7,032
| Closed | -$20K | – | 4756 |
|
|
2022
Q2 | $20K | Hold |
7,032
| – | – | ﹤0.01% | 4625 |
|
|
2022
Q1 | $24K | Hold |
7,032
| – | – | ﹤0.01% | 4652 |
|
|
2021
Q4 | $43K | Hold |
7,032
| – | – | ﹤0.01% | 4615 |
|
|
2021
Q3 | $97K | Hold |
7,032
| – | – | ﹤0.01% | 4409 |
|
|
2021
Q2 | $120K | Sell |
7,032
-33,325
| -83% | -$563K | ﹤0.01% | 4319 |
|
|
2021
Q1 | $763K | Sell |
40,357
-4,284
| -10% | -$138K | ﹤0.01% | 3688 |
|
|
2020
Q4 | $1.29M | Buy |
44,641
+2,795
| +7% | +$80.7K | ﹤0.01% | 3406 |
|
|
2020
Q3 | $1.57M | Buy |
41,846
+16,941
| +68% | +$495K | ﹤0.01% | 3169 |
|
|
2020
Q2 | $830K | Buy |
24,905
+21,749
| +689% | +$942K | ﹤0.01% | 3417 |
|
|
2020
Q1 | $113K | Buy |
3,156
+1,581
| +100% | +$67.3K | ﹤0.01% | 3795 |
|
|
2019
Q4 | $69K | Buy |
+1,575
| New | +$40.3K | ﹤0.01% | 4008 |
|
|
2019
Q2 | – | Sell |
-775
| Closed | -$24K | – | 4292 |
|
|
2019
Q1 | $24K | Hold |
775
| – | – | ﹤0.01% | 4117 |
|
|
2018
Q4 | $20K | Hold |
775
| – | – | ﹤0.01% | 4153 |
|
|
2018
Q3 | $25K | Hold |
775
| – | – | ﹤0.01% | 4202 |
|
|
2018
Q2 | $27K | Buy |
+775
| New | +$22.7K | ﹤0.01% | 4189 |
|
|
2017
Q4 | – | Sell |
-192
| Closed | -$7K | – | 4267 |
|
|
2017
Q3 | $7K | Hold |
192
| – | – | ﹤0.01% | 4214 |
|
|
2017
Q2 | $7K | Hold |
192
| – | – | ﹤0.01% | 4237 |
|
|
2017
Q1 | $10K | Buy |
+192
| New | +$11.3K | ﹤0.01% | 4194 |
|
Northern Trust's SLNO Position: Q2 2026 in Review
Northern Trust sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 393,523 shares — an estimated $13.2M sold.
Northern Trust first reported a position in SLNO in Q1 2017 and held it in 29 quarters. The position peaked at $27.5M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Northern Trust reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Northern Trust sold 393,523 Soleno Therapeutics shares in Q2 2026, an estimated $13.2M.
- Northern Trust first reported a position in Soleno Therapeutics in Q1 2017 and held it in 29 quarters.
- Northern Trust's Soleno Therapeutics position peaked at $27.5M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.